Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 147.45 -0.01 (-0.01%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 Next > Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review November 04, 2022 A mixed jobs report and heavy earnings swung stocks. Via Investor's Business Daily Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat November 01, 2022 The company raised its guidance for Ingrezza sales in 2022. Via Investor's Business Daily Neurocrine Biosciences: Q3 Earnings Insights November 01, 2022 Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga 3 Top Biotech Stocks Defying the Bear Market October 11, 2022 Bear market, shmear market. These biotech stocks are soaring despite the market downturn. Via The Motley Fool Neurocrine Biosciences Buys UK-Based Hormone Therapy Player August 30, 2022 Via Benzinga Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance August 05, 2022 Via Benzinga Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat? August 04, 2022 Neurocrine says the essential tremor drug didn't hit its goals in a key study. Via Investor's Business Daily Earnings Scheduled For November 1, 2022 November 01, 2022 Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 October 11, 2022 Upgrades Via Benzinga Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors September 29, 2022 Via AB Newswire 4 Analysts Have This to Say About Neurocrine Biosciences September 26, 2022 Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2022 September 26, 2022 Upgrades Via Benzinga S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market September 24, 2022 Eli Lilly leads medical stocks setting up and showing relative strength. Via Investor's Business Daily S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms September 17, 2022 Devon Energy leads this weekend's watch list of stocks in a tough market. Via Investor's Business Daily Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin September 15, 2022 The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. Via Investor's Business Daily Neurocrine Leads 5 Stocks To Watch In Sickly Market September 03, 2022 Neurocrine Biosciences leads five medical stocks showing resilience. Via Investor's Business Daily Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases August 05, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review August 05, 2022 The Nasdaq and small caps rose while the S&P 500 is hitting resistance. Via Investor's Business Daily Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate August 04, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points July 23, 2022 Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries. Via Investor's Business Daily Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study July 11, 2022 Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. Via Benzinga Neurocrine Biosciences Earnings Perspective: Return On Capital Employed May 19, 2022 According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60... Via Benzinga The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product May 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Neurocrine Biosciences: Q1 Earnings Insights May 04, 2022 Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Via Benzinga Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET April 25, 2022 Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. Via Benzinga What 8 Analyst Ratings Have To Say About Neurocrine Biosciences April 04, 2022 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Via Benzinga The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia March 29, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022 March 03, 2022 Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,... Via Benzinga Where Neurocrine Biosciences Stands With Analysts February 25, 2022 Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022 February 25, 2022 Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,... Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.